C4X Discovery Holdings Plc

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: GB00BQQ2RV18
GBP
0.12
0.03 (27.25%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

3.77 M

Shareholding (Dec 2021)

FII

19.36%

Held by 3 FIIs

DII

0

Held by 4 DIIs

Promoter

23.20%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a growth in Net Profit of NAN%, the company declared Very Positive results in Jan 24

  • OPERATING CASH FLOW(Y) Highest at GBP -3.4 MM
  • NET SALES(HY) Higher at GBP 24.65 MM
  • ROCE(HY) Highest at 55.38%
2

With ROE of 42.9, it has a very attractive valuation with a 1.2 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

GBP 30 Million (Micro Cap)

stock-summary
P/E

3.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.52

stock-summary
Return on Equity

42.94%

stock-summary
Price to Book

1.23

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.44%
0%
-11.44%
6 Months
-15.49%
0%
-15.49%
1 Year
-20.53%
0%
-20.53%
2 Years
-62.2%
0%
-62.2%
3 Years
-71.43%
0%
-71.43%
4 Years
-22.58%
0%
-22.58%
5 Years
-79.24%
0%
-79.24%

C4X Discovery Holdings Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
28.44%
EBIT Growth (5y)
33.30%
EBIT to Interest (avg)
-4.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.52
Sales to Capital Employed (avg)
0.41
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.05%
ROE (avg)
8.59%
Valuation key factors
Factor
Value
P/E Ratio
3
Industry P/E
Price to Book Value
1.23
EV to EBIT
1.85
EV to EBITDA
1.78
EV to Capital Employed
1.48
EV to Sales
0.70
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
80.23%
ROE (Latest)
42.94%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2021stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 3 Foreign Institutions (19.36%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by C4X Discovery Holdings Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jul'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jul 2023 is -37.04% vs -51.79% in Jul 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jul 2023 is -35.37% vs -115.79% in Jul 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jul'23",
        "Jul'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.70",
          "val2": "2.70",
          "chgp": "-37.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.90",
          "val2": "-10.30",
          "chgp": "-25.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.10",
          "val2": "-8.20",
          "chgp": "-35.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-7,754.40%",
          "val2": "-3,898.50%",
          "chgp": "-385.59%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Jul'23stock-summary
Jul'23
Jul'22
Change(%)
Net Sales
1.70
2.70
-37.04%
Operating Profit (PBDIT) excl Other Income
-12.90
-10.30
-25.24%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.10
-8.20
-35.37%
Operating Profit Margin (Excl OI)
-7,754.40%
-3,898.50%
-385.59%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Jul 2023 is -37.04% vs -51.79% in Jul 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jul 2023 is -35.37% vs -115.79% in Jul 2022

stock-summaryCompany CV
About C4X Discovery Holdings Plc stock-summary
stock-summary
C4X Discovery Holdings Plc
Pharmaceuticals: Major
C4X Discovery Holdings plc is a drug discovery and development company. The Company is engaged in the provision of technologies to improve the drug discovery process for small molecule therapies. Its discovery portfolio targets addiction, diabetes, inflammatory diseases and oncology, and includes small molecule versions of marketed biologics. Its products include Orexin-1, NRF-2, GPR142, GLP-1, Anti-IL-17, SGC Collaboration and Target 1. Its primary indication for its oral Orexin-1 antagonists is for the treatment of nicotine addiction as an aid to smoking cessation. It has two drug discovery programs targeting inflammatory disorders: oral Nrf-2 activators for the treatment of Chronic Obstructive Pulmonary disease (COPD) and oral/topical IL-17 inhibitors for the treatment of Psoriasis. IL-17 is implicated in multiple inflammatory and autoimmune diseases. Its suite of technologies include Taxonomy3, Conformetrix and MolPlex.
Company Coordinates stock-summary
Company Details
Manchester One, 53 Portland Street , MANCHESTER None : M1 3LD
Registrar Details